Relative efficacy of lasmiditan versus rimegepant and ubrogepant as acute treatments for migraine: network meta-analysis findings

Table 2 Included studies: interventions and outcomes assessed in the NMA

Studies included	Interventions studied and assessed in the NMA	Pain freedom at 2 hours	Pain relief at 2 hours	Pain relief at 1 hour	MBS freedom at 2 hours	Sustained pain freedom over 24 hours	Pain freedom at 30 min	Pain freedom at 1 hour	MBS freedom at 1 hour	Pain relief at 30 min
Lasmiditan vs placebo
SAMURAI Kuca et al. 2018 [15]	Lasmiditan 100 mg, 200 mg	✓	✓	✓	✓	✓	✓	✓	✓	✓
SPARTAN Goadsby et al. 2019 [16]	Lasmiditan 50 mg, 100 mg, 200 mg	✓	✓	✓	✓	✓	✓	✓	✓	✓
CENTURION Ashina et al. 2021 [17]	Lasmiditan 100 mg, 200 mg	✓	✓	✓	✓	✓	✓	✓	✓	✓
MONONOFU Sakai et al. 2021 [18]	Lasmiditan 50 mg, 100 mg, 200 mg	✓	✓	✓	✓	✓	✓	✓	✓	✓
Färkkilä et al. 2012 [19]	Lasmiditan 50 mg, 100 mg, 200 mg	✓	✓
Rimegepant vs placebo
Study 301 Lipton et al. 2018 [20]	Rimegepant 75 mg tablets	✓	✓		✓	✓
Study 302 Lipton et al. 2019 [21]	Rimegepant 75 mg tablets	✓	✓		✓	✓
Study 303 Croop et al. 2019 [22]	Rimegepant 75 mg ODT	✓	✓	✓	✓	✓				✓
Marcus et al. 2014 [23]	Rimegepant 75 mg tablets	✓	✓			✓
Ubrogepant vs placebo
ACHIEVE I Dodick et al. 2019 [24]	Ubrogepant 50 mg, 100 mg	✓	✓		✓	✓
ACHIEVE II Lipton et al. 2019 [25]	Ubrogepant 25 mg, 50 mg	✓	✓		✓	✓
Voss et al. 2016 [26]	Ubrogepant 25 mg, 50 mg, 100 mg	✓	✓			✓
ACHIEVE I + ACHIEVE II pooled data Goadsby et al. 2021 [27]	Ubrogepant 50 mg	✓		✓	✓		✓	✓	✓	✓

Bold ticks denote the primary endpoint(s) of the study
MBS most bothersome symptom, NMA network meta-analysis, ODT oral disintegrating tablet

ISSN: 1129-2377